Ferring Pharmaceuticals of Denmark has expanded its partnership with Antares Pharma covering the latter's needle-free delivery devices. Ferring already markets the Exton, Pennsylvania firm's Medi-Jector Vision device for use with the growth hormone product, Zomacton. It now plans to access newer versions of Antares' devices at a cost of E1.5m ($1.6m). The currently marketed product, branded Zomajet 2 Vision, is a reusable spring-loaded device that loads the drug from a vial and delivers it as a fine liquid stream.
Ferring commits further to Antares devices:
Ferring Pharmaceuticals of Denmark has expanded its partnership with Antares Pharma covering the latter's needle-free delivery devices. Ferring already markets the Exton, Pennsylvania firm's Medi-Jector Vision device for use with the growth hormone product, Zomacton. It now plans to access newer versions of Antares' devices at a cost of E1.5m ($1.6m). The currently marketed product, branded Zomajet 2 Vision, is a reusable spring-loaded device that loads the drug from a vial and delivers it as a fine liquid stream.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
• By
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
• By
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
• By
FDA moves forward with implementing previous draft guidance and will consolidate forms, but the agency estimates limited impact in the total reporting burden.
• By
Ultrahuman seeks to “create an environment that aligns with our bodies" by linking environmental parameters collected by Ultrahuman Home to health physiology, measured by the Ultrahuman Ring Air.
• By
The US FDA's new draft guidance details the responsibilities of new owners of 510(k) clearances, including making timely updates device listings in FURLS and GUDID to maintain accurate information for safety alerts and recalls. Comments on the draft are accepted until 4 August.